Attenuated EAN in TNF-α Deficient Mice Is Associated with an Altered Balance of M1/M2 Macrophages by Zhang, Hong-Liang et al.
Attenuated EAN in TNF-a Deficient Mice Is Associated
with an Altered Balance of M1/M2 Macrophages
Hong-Liang Zhang











1Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden, 2Department of Pharmacology, Faculty of Medicine and Health
Sciences, United Arab Emirates University, Al Ain, United Arab Emirates, 3Center for Infectious Medicine, Department of Medicine, Karolinska Institute, Karolinska
University Hospital Huddinge, Stockholm, Sweden, 4Department of Neurology, University of Rostock, Rostock, Germany, 5Department of Neurology, First Hospital of Jilin
University, Changchun, China
Abstract
The role of tumor necrosis factor (TNF)-a and its receptors in neuroautoimmune and neuroinflammatory diseases has been
controversial. On the basis of our previous studies, we hereby aimed to further clarify TNF-a’s mechanism of action and to
explore the potential role of TNF-a receptor (TNFR)1 as a therapeutic target in experimental autoimmune neuritis (EAN).
EAN was induced by immunization with P0 peptide 180–199 in TNF-a knockout (KO) mice and anti-TNFR1 antibodies were
used to treat EAN. Particularly, the effects of TNF-a deficiency and TNFR1 blockade on macrophage functions were
investigated. The onset of EAN in TNF-a KO mice was markedly later than that in wild type (WT) mice. From day 14 post
immunization, the clinical signs of TNF-a KO mice were significantly milder than those of their WT counterparts. Further, we
showed that the clinical severity of WT mice treated with anti-TNFR1 antibodies was less severe than that of the control WT
mice receiving PBS. Nevertheless, no difference with regard to the clinical signs of EAN or inflammatory infiltration in cauda
equina was seen between TNF-a KO and WT mice with EAN after blockade of TNFR1. Although TNF-a deficiency did not
alter the proliferation of lymphocytes in response to either antigenic or mitogenic stimuli, it down-regulated the production
of interleukin (IL)-12 and nitric oxide (NO), and enhanced the production of IL-10 in macrophages. Increased ratio of
regulatory T cells (Tregs) and reduced production of interferon (IFN)-c in cauda equina infiltrating cells, and elevated levels
of IgG2b antibodies against P0 peptide 180–199 in sera were found in TNF-a KO mice with EAN. In conclusion, TNF-
a deficiency attenuates EAN via altering the M1/M2 balance of macrophages.
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Introduction
Guillain-Barre ´ syndrome (GBS) is an inflammatory demyelin-
ating disorder of the peripheral nervous system (PNS) in humans.
The clinical feature of GBS is characterized by rapidly progressive
weakness and sensory dysfunction in the limbs as well as
respiratory weakness [1]. The exact pathogenesis of GBS remains
largely unknown. Experimental autoimmune neuritis (EAN) shares
clinical, histopathological, and electrophysiological features with
GBS and hence can be employed as an animal model to explore its
pathogenesis. Pathologically, EAN is attributable to breakdown of
the blood-nerve barrier (BNB), robust accumulation of reactive T
cells and macrophages in the PNS and demyelination of peripheral
nerves [2]. In order to cross the BNB and to provoke a local
inflammatory response, circulating autoreactive T cells need to be
activated and to produce proinflammatory cytokines, including
tumor necrosis factor (TNF)-a, interleukin (IL)-1 and IL-6 [3].
Macrophages are the predominant cell population in the lesions of
GBS and EAN [4]. As professional antigen presenting cells,
macrophages express major histocompatibility complex (MHC)-II
and co-stimulatory B7 molecules, and thus are critical in the
activation of T helper (Th) cells and the triggering of the
autoimmune process. Moreover, macrophages are crucial in the
effector phase of EAN via phagocytotic attack and secretion of
inflammatory mediators such as TNF-a and nitric oxide (NO) [5].
TNF-a is a Th1 cytokine that is expressed on activated
macrophages, T cells, NK cells, and, to a lesser extent, on tissue
cells such as endothelial cells, smooth muscle cells, fibroblasts,
astrocytes, neurons and Schwann cells (SCs). Depending on
binding to different TNF-a receptors (TNFRs), i.e. TNFR1 or
TNFR2, TNF-a bears proinflammatory or antiinflammatory
properties [6]. Polymorphisms of TNF-a and its promoter have
been associated with susceptibility to GBS [7]. TNF-a has been
identified as a key player in the pathogenesis of GBS and EAN.
Clinically, an increased level of TNF-a in serum has been
correlated with the disease severity of GBS [8,9]. Likewise, levels
of TNF-a in serum decrease after immunomodulatory treatment
and are in parallel with clinical recovery of GBS patients [10].
Expression of TNF-a mRNA in the PNS is upregulated at nadir of
clinical EAN [11]. TNF-a positive macrophages appear in
peripheral nerves around the onset of EAN [12]. Levels of TNF-
a producing cells in blood, lymph nodes and PNS tissue roughly
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a into rat sciatic nerves resulted in inflammatory vascular changes
within the endoneurium along with demyelination and axonal
degeneration [13]. Furthermore, systemic administration of TNF-
a markedly worsened EAN [14]. Conversely, treatment with
monoclonal antibodies (mAb) against TNF-a or soluble TNFR1
ameliorated EAN [15,16]. In addition, antiinflammatory com-
pounds such as rolipram, linomede and leflunomide markedly
inhibited cellular infiltration and downregulated production of
TNF-a, and by doing so, suppressed the clinical symptoms of EAN
[17–19].
To further clarify the role of TNF-a in the pathogenesis of EAN
and to explore the potential of TNFR1 as a therapeutic target in
GBS, we induced EAN in TNF-a KO mice and studied the effect
of TNFR1 blockade with anti-TNFR1 antibodies on EAN.
Specifically, the effects of TNF-a deficiency and TNFR1 blockade
on macrophage functions were investigated.
Materials and Methods
Ethics Statement
The EAN model on mice was approved by the South
Stockholm Research Animal Ethics Committee, Huddinge Coun-
ty Court, Stockholm (S40-11) and the Animal Research Ethics
Committee, Faculty of Medicine & Health Sciences, United Arab
Emirates (UAE) University, Al Ain, UAE (A11/11).
Animals
TNF-a KO and and wild type (WT) mice were purchased from
Taconic (Taconic, Ry, Demark) and housed at the animal facility
of the Faculty of Medicine and Health Sciences, UAE University,
Al Ain, UAE. Male mice, 5–6 weeks old were used for the study.
All mice were housed on a 12/12 light-dark schedule with water
and food available ad libitum.
Antigen
The neuritogenic P0 peptide 180–199
(SSKRGRQTPVLYAMLDHSRS) of murine PNS myelin P0
protein was synthesized by the 9-fluorenylmethoxycarbonyl
(Fmoc) solid-phase procedure [20], purified by high-performance
liquid chromatography (HPLC) using a Vydac reverse-phase
column (Grace Vydac, Hesperia, CA, USA), and analyzed by
matrix-assisted laser desorption/ionization (MALDI) time-of-flight
(TOF) mass spectrometry (Cambridge Research Biochemicals,
Billingham, UK).
Induction of the EAN Model and Assessment of the
Clinical Course
Emulsion of P0 peptide and Freund’s complete adjuvant (FCA)
was prepared by gently adding P0 peptide solution in 0.9% saline
to FCA being vortexed. FCA refers to Mycobacterium tuberculosis plus
Freund’s incomplete adjuvant (FIA). EAN was induced by
immunizing mice twice (days 0 and 8) via subcutaneous injection
of 150 mg P0 peptide 180–199, 0.5 mg Mycobacterium tuberculosis
(strain H37 RA; Difco, Franklin Lakes, NJ, USA) in 25 ml saline,
and 25 ml FIA (ICN Biomedicals, Costa Mesa, CA, USA) to the
back of mice. All mice received 400, 300, and 300 ng pertussis
toxin (PTX, Merck, Whitehouse Station, NJ, USA) by intravenous
injection (via tail veins) on days 21, +1 and +3 post immunization
(p.i.), respectively. Using a blinded protocol, two examiners
assessed clinical signs of mice with EAN immediately before
immunization (day 0) and thereafter every two days until day
59 p.i. EAN was scored as follows: 0, normal; 1, less lively, reduced
tone of the tail; 2, flaccid tail; 3, abnormal gait; 4, ataxia; 5, mild
paraparesis; 6, moderate paraparesis; 7, severe paraparesis; 0.5,
intermediate clinical signs.
Lymphocyte Proliferation Test
Mice were sacrificed at the height of EAN (day 28 p.i.) after
perfusion with phosphate-buffered saline (PBS). Spleens were
removed and single cell suspensions of mononuclear cells (MNCs)
in RPMI-1640 (Invitrogen, Carlsbad, CA, USA) were prepared
and cultured. Concanavalin A (ConA, 10 mg/ml, Sigma-Aldrich,
St. Louis, MO, USA), P0 peptide 180–199 (10 mg/ml) and IL-23
(100 ng/ml, eBioscience, San Diego, CA, USA) were used as
stimuli. The concentrations had maximum stimulatory effects as
assessed in pilot experiments. After 60 h of cultivation with
respective stimulus, the proliferation was assessed using the
CellTiter 96H AQueous One Solution Cell Proliferation Assay
(Promega Corporation, Madison, WI, USA) according to the
manufacturer’s instructions. Briefly, assays were performed by
adding a small amount of the reagent directly to culture wells. The
CellTiter 96H AQueous One Solution Cell Proliferation Assay
contains a novel tetrazolium compound [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt; MTS(a)]. The MTS tetrazolium compound is
bioreduced into a colored formazan product soluble in cell culture
medium by NADPH or NADH produced by dehydrogenase in
metabolically active cells. After 4 h incubation, the absorbance at
490 nm was recorded with an ELISA reader (Tecan, Ma ¨nnedorf,
Switzerland).
Isolation of Infiltrating Cells in the Cauda Equina (CE)
CE infiltrating cells were isolated according to method de-
scribed by Duan, et al [21]. Briefly, CE fragments were carefully
removed from PBS perfused mice, transferred to RPMI-1640,
ground and passed through a 70 mm cell nylon mesh (Becton
Dickinson, Franklin Lakes, NJ, USA). The collected cells were
suspended in 27% Percoll (Amersham Biosciences AB, Uppsala,
Sweden) in PBS and centrifuged at 10006g for 30 min at 4uC.
The pellets were harvested.
Macrophage Cultures and NO Detection
Mice were sacrificed and standard lavage of the peritoneal
exudates with 10 ml serum-free culture medium DMEM/F12
(Invitrogen) was performed. The lavage fluid contained peritoneal
exudate mononuclear cells (PEMs), which represented mainly
macrophages as tested by labeling with the macrophage marker
macrosialin (mouse equivalent of human CD68). The single cell
suspension was centrifuged at 3006g for 10 min. The pellets were
re-suspended with DMEM/F12 supplemented with 5% fetal
bovine serum (FBS, Sigma-Aldrich), 100 IU/ml penicillin and
100 mg/ml streptomycin (both from Gibco-Invitrogen, Grand
Island, NY, USA). Macrophages were seeded into 5.3 cm Petri-
dishes (Becton Dickinson, San Jose, CA, USA) at a concentration
of 2610
6/ml. The cultured cells were stimulated with lipopoly-
saccharide (LPS, Sigma-Aldrich, 100 ng/ml), recombinant mouse
interferon (IFN)-c (Hycult Biotechnology, Uden, The Netherlands,
100 IU/ml), IL-12 (Sigma-Aldrich, 10 ng/ml), TNF-a (Sigma-
Aldrich, 5 ng/ml), polyinosinic-polycytidylic acid (poly I:C,
Sigma-Aldrich, 50 mg/ml), combinations thereof, LPS (500 ng/
ml), and IFN-c (500 IU/ml). After 24 h incubation, the super-
natants were collected and snap-frozen for cytokine and NO
detection. After removal of the supernatants, macrophages
stimulated with 100 ng/ml LPS plus 100 IU/ml IFN-c were
incubated with Brefeldin A (3 mg/ml, eBioscience) in order to
inhibit further cytokine secretion. After 6 h, these macrophages
were harvested for subsequent flow cytometric analysis of in-
TNF-a and EAN
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detecting the supernatant levels of nitrite, the stable biological
oxidation product of NO using the modified Griess reagent
(Sigma-Aldrich). The detecting procedure was performed
according to the manufacturer’s instructions. The concentrations
of nitrite were quantified by extrapolation from the standard
curve obtained by using sodium nitrite (Sigma-Aldrich) solutions
at concentrations of 9, 3, 1, 0.33, 0.11, 0.033, and 0 mg/ml.
Flow Cytometry
FITC-, PE-, APC- and PerCP-conjugated antibodies were
purchased from commercial suppliers. Specifically, anti-mouse-
macrosialin monoclonal antibodies were from AbD Serotec
(Kidlington, UK); anti-mouse-CD3, CD4, CD8, CD25, CD16/
32, CD45, NK1.1, dendritic cell marker, T cell receptor (TCR), B
cell receptor (BCR), IL-4, IL-10, IL-12, IL-17A, IL-17F, IFN-c,
TNF-a, MCP-1, CXCL9, abTCR and cdTCR monoclonal
antibodies, and mouse-FoxP3 staining set were from eBioscience;
and anti-mouse-CD45 monoclonal antibodies were from BD
Biosciences (San Jose, CA, USA). Monoclonal antibodies against
MHC-II, CD86 and TNFR2 were from Abcam (Cambridge, UK).
Cells (CE infiltrating cells, splenic MNCs or PEMs) were harvested
and washed with 1% bovine serum albumin (BSA, Sigma-Aldrich)
in PBS. For staining of molecules with extracellular expression,
cells were incubated with FITC-, PE-, APC, and/or PerCP-
conjugated antibodies for 15 min at room temperature (RT). The
staining of FoxP3 was according to instructions provided by the
manufacturer. For staining of other molecules with intracellular
expression, cells were fixed with 2% paraformaldehyde (Merck) for
15 min at RT and permeabilized with 0.5% freshly prepared
saponin (Sigma-Aldrich) in PBS containing 1% BSA. The
permeabilized cells were incubated with FITC-, PE-, APC, and/
or PerCP-conjugated antibodies for 15 min at RT. FITC-, PE-,
APC- and PerCP-conjugated isotype antibodies (from BD
Biosciences) were used as negative controls. Cells were washed
twice, resuspended in 1% paraformaldehyde in PBS and stored at
4uC until flow cytometric analysis with an FACSCanto
TM II
cytometer (Becton Dickinson) using the FACSDiva software
(Becton Dickinson). Surface and intracellular molecule expressions
were assessed by determining the positive cell percentage. In each
experiment, cells from all groups were collected and analyzed at
each time-point on the same day with the same cytometer settings.
Flow cytometric data were analyzed with the CellQuest Pro
software (Becton Dickinson) or FlowJo (TreeStar, Ashland, OR,
USA).
ELISA for Measuring Cytokines in Sera and Cell Culture
Supernatants
A standardized procedure for the sandwich ELISA was
established after optimization of experimental parameters. Coat-
ing and detecting antibodies against mouse IL-6, IL-10, IL-12, IL-
17A, and IFN-c, and recombinant mouse IL-6, IL-10, IL-12, IL-
17A, and IFN-c proteins as standards, respectively, were
purchased from eBioscience. Briefly, monoclonal antibodies were
coated onto standard ELISA plates (Nalge Nunc, Roskilde,
Denmark) in a volume of 100 ml/well overnight at 4uC. After
three washings with PBS, uncoated sites were blocked with 100 ml
10% FBS in PBS for 1 h at RT. Duplicates of samples (sera or
macrophage supernatants) or of recombinant standards were
added and the plates were incubated for 1 h at RT. After washing,
the plates were incubated with biotinylated detecting antibody
against IL-6, IL-10, IL-12, IL-17A, and IFN-c (eBioscience),
respectively, for 2 h at RT. Then avidin-conjugated horseradish
peroxidase (HRP, eBioscience) was added for 30 min. Color
reaction was performed with 100 ml of tetramethylbenzidine
(TMB, Sigma-Aldrich) for 30 min and the reaction was terminated
by adding 2 M sulfuric acid (Sigma-Aldrich). The plates were
immediately read at 450 nm with an ELISA reader (Tecan). The
concentrations of proteins were quantified by extrapolation from
the standard curve.
ELISA for Measurement of anti-P0 Peptide 180–199
Antibodies in Sera
Serum samples were obtained from mice at the peak of EAN
disease (day 28 p.i.). Samples of groups of 8–10 mice were pooled.
P0 peptide 180–199 was coated overnight at 4uC by adding
10 mg/ml in 100 ml per well onto ELISA plates. After three
washings with PBS, uncoated sites were blocked with 100 ml 10%
FBS in PBS for 2 h at RT. After three washings, serum samples
were diluted at 1:100 with 1% BSA in PBS, applied to plate wells
and incubated for 1.5 h at RT. Then plates were incubated for 1 h
with peroxidase-conjugated affinipure rabbit anti-mouse IgM,
IgG, IgG1, IgG2a, IgG2b (Jackson ImmunoResearch Laborato-
ries, West Grove, PA, USA) after dilution at 1:5000 with 1% BSA
in PBS. After three washings, the peroxidase substrate TMB
(Sigma-Aldrich) was added and 15–30 min later the reaction was
terminated by adding 2 M sulfuric acid (Sigma-Aldrich). The
plates were read at 450 nm using an ELISA reader (Tecan).
TNFR1 Blocking
Anti-TNFR1 monoclonal antibodies (Santa Cruz Biotechnolo-
gy, Santa Cruz, CA, USA) were administered intravenously to
WT mice (n=5) with EAN at a dose of 200 mg/(kg body weight)
on days 21, +3 and +7 p.i., respectively. Another group of age-
and sex-matched WT mice (n=5) received 0.9% saline as
controls. Using a blinded protocol, two examiners assessed clinical
signs of EAN mice every two days until day 35 p.i. according to
the scale described above.
In a separate experiment, the TNFR1 blocking was performed
in both TNF-a KO and WT mice after induction of EAN. The
procedure with immunization and anti-TNFR1 monoclonal
antibody treatment was as described above. The clinical severity
of EAN was assessed until day 35 p.i. (n=5 in both groups) and
flow cytometry was used to assess the CE infiltrating cells on the
day 28 p.i. in TNF-a KO and WT mice with EAN after blocking
TNFR1 functions (n=5 in both groups).
Statistics
Data have been expressed as mean value 6 standard deviation
(SD). The Statistical Package for the Social Sciences 14.0 (SPSS,
IBM, West Grove, PA, USA) was used for analyzing all data. One-
way analysis of variance (ANOVA) and Kruskal-Wallis test were
used to compare values among groups followed by Student’s t-test
or Mann-Whitney u-test to compare values between groups. All
tests were two-tailed, with the level of significance set to p,0.05.
Results
TNF-a Deficiency Attenuates the Clinical Severity of EAN
All mice immunized with P0 peptide 180–199 in combination
with FCA acquired EAN. The onset of EAN in the TNF-a KO
group was later than in WT group (9–13 days versus 7–9 days p.i.).
EAN reached the peak of the disease on day 28 p.i. in TNF-a KO
mice and on day 25 p.i. in WT mice, respectively. Disease
persisted until around day 38 p.i. when evidence of recovery
became discernible. Almost all the mice had recovered completely
by day 59 p.i. From day 14 p.i., the clinical signs of TNF-a KO
TNF-a and EAN
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(Mann-Whitney u-test, all p,0.05, Figure 1).
TNF-a Deficiency Does not Alter Priming Responses of
Splenic MNCs
At nadir of EAN (day 28 p.i.), splenic MNCs of mice were
cultured and stimulated with P0 peptide 180–199 and ConA for
antigenic and mitogenic proliferation. For both sets of stimulation,
the proliferation was higher in EAN mice than in naı ¨ve mice
(p,0.05 for all comparisons, data not shown). However, there was
neither any significant difference between naı ¨ve TNF-a KO and
naı ¨ve WT mice, nor between EAN TNF-a KO and EAN WT
mice (data not shown). There was also no significant difference
between TNF-a KO and WT mice with EAN, even after
stimulation with IL-23 to induce the proliferation of armed
effector T cells (data not shown).
TNF-a Deficiency Down-regulated the Proinflammatory
Phenotype of Macrophages
EAN mice were sacrificed at nadir of disease (day 28 p.i.) and
CE infiltrating cells were analyzed by flow cytometry (Figure 2A).
The infiltrating macrophages (Figure 2B) from TNF-a KO mice
exhibited reduced levels of IL-12 (Figure 2C and 2E) and similar
levels of IL-10 (Figure 2D), when compared with those from WT
mice. Furthermore, the ratio of the percentages of IL-12
expressing cells to that of IL-10 expressing cells was lower in CE
infiltrating cells from TNF-a KO mice than from WT mice
(Figure 2F).
In addition, at the peak of EAN, non-stimulated PEMs were
collected for flow cytometric analysis. TNF-a deficient PEMs
expressed reduced levels of IL-12 as compared with their WT
counterparts (Figure 2G).
Thioglycollate (Fluka, Milwaukee, WI, USA) elicited PEMs
were cultured and stimulated with LPS plus IFN-c for 24 h. Flow
cytometry was used to assess cytokine production. Cultured PEMS
represented mainly macrophages as tested by labeling with the
macrophage marker macrosialin (Figure 3A–3C). Two subgroups
of PEMs from EAN mice were present in Figure 3A according to
their light scatter properties. The group of cells with larger size
expressed higher levels of IL-6 and IL-12 indicating a stronger
activation of these cells. The proportion of more activated PEMs
was higher in EAN than naı ¨ve mice [22]. In EAN, the proportion
of more activated PEMs was markedly lower in TNF-a KO mice
than in WT mice (Figure 3D). Macrophages from TNF-a KO
mice expressed lower levels of IL-12 (Figure 3E and 3F) and higher
levels of IL-10 (Figure 3G and 3H) as compared with those from
WT mice independent of EAN induction.
Supernatants of PEM cultures were collected for cytokine
production assessment. Without stimulation, macrophages from
TNF-a KO mice (both naı ¨ve and EAN mice) produced higher
levels of IL-6 than those from WT mice, whereas after stimulation,
macrophages from TNF-a KO mice produced lower levels of IL-6
than those from WT mice (p,0.01, Figure 4A). For IL-12
production, the only significant finding was a lower cytokine
production by stimulated macrophages from EAN TNF-a KO
mice than from EAN WT mice (p,0.01, Figure 4B). For IL-10
production, the opposite was the case, i.e. stimulated as well as
Figure 1. Attenuated clinical severity of EAN in TNF-a KO versus WT mice. EAN was induced in TNF-a KO mice and WT mice by
immunization with P0 peptide 180–199 in combination with FCA. Using a blinded protocol, two examiners evaluated the clinical severity of EAN mice
immediately before immunization (day 0 p.i.) and thereafter every two days until day 59 p.i. From day 14 p.i., the clinical signs of TNF-a KO mice were
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produced higher levels of IL-10 than those from EAN WT mice
(p,0.01, Figure 4C).
No significant differences were found with regard to the
expression of TNFR2, IL-4, MCP-1 and CXCL9, respectively,
on or in CE infiltrating cells, as well as with regard to the
proportions of abTCR
+ and cdTCR
+ cells relative to total
infiltrating cells (data not shown). Likewise, no significant
differences were found with regard to the expressions of TNFR2,
MCP-1 and CXCL9, respectively, on cultured macrophages (data
not shown).
Macrophages from naı ¨ve and EAN mice were cultured and
stimulated with LPS, IFN-c, IL-12, poly I:C, and combinations
thereof. In each set of stimulation, NO production was lower in
TNF-a KO group than in the WT group (p,0.05 for all
comparisons, Figure 5). For the TNF-a stimulated set, NO
production was higher in EAN TNF-a deficient macrophages than
in EAN WT macrophages (0.9260.24 mg/ml versus
0.4460.14 mg/ml). Upon TNFR1 blockade, NO was almost
undetectable in macrophage cultures, independent of TNF-a gene
status and EAN induction.
TNF-a Deficiency Increases Tregs and Reduces IFN-c
Production
CE infiltrating cells and splenic MNCs were analyzed at nadir
of EAN (day 28 p.i.) by flow cytometry. Cell debris was excluded
by proper gating. The yield regarding CE infiltrating cells and
splenic MNCs was similar between or among groups (data not
shown). We routinely detected the proportion of different immune
cell subsets in naı ¨ve and EAN conditions by using labeled
antibodies against CD3, CD4, CD8, CD45, NK1.1, dendritic cell
marker, TCR, BCR, macrosialin, etc. No significant difference
was seen regarding the proportions of different cell subsets (the
CD4
+ subset, the macrosialin
+ subset, and the CD8
+ subset, etc.,
data not shown).




accounted for more than 90% of the total CE infiltrating cells,
and the other cells including CD8
+TCR
+ cells, dendritic cells, NK




+) in CE infiltrating cells was higher in
TNF-a KO than in WT mice with EAN (p,0.05, Figure 6A–6C).
The percentage of IFN-c expressing cells relative to CD4
+ CE
infiltrating cells was lower in TNF-a KO than in WT mice with
EAN (p,0.05, Figure 6D and 6E). The same was also true for
splenic MNCs in EAN, but not in naı ¨ve mice (p,0.05, Figure 6F).
TNF-a Deficiency Decreases Levels of Anti-P0 Peptide
180–199 IgG2b Antibodies
Serum samples of mice at nadir of EAN (day 28 p.i.) were
analyzed by ELISA for anti-P0 peptide 180–199 antibodies (IgM,
pan-IgG, IgG1, IgG2a and IgG2b). The concentrations of IgG2b
(OD values at 450 nm) were significantly lower in TNF-a KO
than WT mice with EAN (0.4260.01 versus 0.4560.01, n=7,
p,0.01). No difference was found with regard to serum
concentrations of IgM, pan-IgG, IgG1 or IgG2a (data not shown).
TNF-a Deficiency Upregulates Production of IL-17A
At nadir of EAN (day 28 p.i.), CD4
+ CE infiltrating cells
(Figure 7A and 7B) contained a higher percentage of IL-17A
+ cells
in TNF-a KO than in WT mice (Figure 7C and 7D). At the same
time-point single cell suspensions of splenic MNCs contained
a higher percentage of CD4
+IL-17A
+ cells (Figure 7E), when the
TNF-a gene was knocked out. The same was also true for naı ¨ve
mice, but at a lower level. Similarly, the concentrations of IL-17A
in sera were higher in TNF-a KO mice than in WT mice, when
EAN mice are regarded. This is in agreement with the finding of
a higher serum level of IL-17A in EAN TNF-a KO compared
with naı ¨ve TNF-a KO mice (Figure 7F).
The Proinflammatory Role of TNF-a in EAN is Mediated
by TNFR1
To further elucidate which receptor is responsible for the
detrimental role of TNF-a in the pathogenesis of EAN, we blocked
the functions of TNFR1 with neutralizing antibodies against
TNFR1 in WT mice. The onset of EAN in the anti-TNFR1
treated group was later than in saline-treated controls (9–13 days
versus 7–9 days p.i., Figure 8). EAN reached the peak of the disease
on day 30 p.i. in the intervention group and on day 27 p.i. in the
control group, respectively. From day 7 p.i., the clinical severity
was significantly milder in the anti-TNFR1-treated group than in
the control group, except on day 11 p.i., when the difference did
not reach statistical significance (Mann-Whitney u-test, Figure 8).
To corroborate the detrimental role of TNFR1 in EAN, we also
blocked the functions of TNFR1 with neutralizing antibodies
against TNFR1 in both TNF-a KO and WT control mice with
EAN. Neither was any significant difference found between groups
as to the onset, the peak or the clinical severity before day 35 p.i.,
nor as to the percentage of Tregs, IFN-c expressing CD4
+ cells or
the ratio of the percentages of IL-12 expressing cells to that of IL-
10 expressing cells in CE infiltrating cells (data not shown).
Discussion
By inducing EAN in TNF-a KO mice, we found that TNF-
a deficiency attenuated the clinical severity of EAN. In accordance
with prior studies, our data support a predominantly detrimental
role of TNF-a in the pathogenesis of EAN. As an important Th1
cytokine, TNF-a contributes to a Th1-polarized immune response
in EAN. TNF-a deficiency may lead to an amelioration of the Th1
immune response, thereby attenuating the clinical severity of
EAN. This is evidenced by a downregulated production of IFN-c
Figure 2. Expression of IL-12 in the CE infiltrating cell and in non-stimulated PEMs of TNF-a KO EAN mice. A. EAN mice were sacrificed
at nadir of disease (day 28 p.i.) and CE infiltrating cells were analyzed by flow cytometry. Generic features of CE infiltrating cells in EAN, as assessed by
light scatter properties (FSC and SSC) in flow cytometry, are shown. B. R1 represents macrophage (macrosialin+) subpopulation (The red histogram
denotes the staining with FITC-conjugated isotype antibody and the green one denotes the staining with anti-CD68 (macrosialin) antibody (Clone:
ED1)). C. Representative flow cytometric data show that CE infiltrating cells of TNF-a KO mice expressed lower levels of IL-12 (blue histogram) than
those of WT mice (green). The histogram in red denotes the staining with PE-conjugated isotype antibody. D. Representative flow cytometric data
indicate similar expressions of IL-10 by CE infiltrating cells of TNF-a KO mice (blue histogram) and of WT mice (green). The red histogram denotes the
staining with PE-conjugated isotype antibody. E. CE infiltrating cells of TNF-a KO mice expressed significantly lower IL-12 levels than those of WT
mice. F. The ratio of the expressing cells of IL-12 to IL-10 was significantly lower in CE infiltrating cells from TNF-a KO mice than from WT mice. G.A t
the peak of EAN (day 28 p.i.), non-stimulated PEMs were collected by standard lavage of peritoneal cavity and the expression of IL-12 was detected
by flow cytometry. TNF-a deficient PEMs expressed significantly lower levels of IL-12 compared with their WT counterparts. Data are presented as
mean value 6 SD of one representative out of two independent experiments (n=5 or 6 in each group). * p,0.05.
doi:10.1371/journal.pone.0038157.g002
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antibodies in EAN TNF-a KO mice.
TNF-a signals through TNFR1 and TNFR2, mainly TNFR1,
to elicit partly opposite reactions in multiple cell types [23]. The
dual effect of TNF-a segregates at the level of the two different
receptors. We found that TNF-a KO mice were not completely
resistant to EAN induction. The reason could be that TNF-a is not
a uniquely necessary inflammatory molecule for the induction of
EAN.
Previously we found conflicting results with regard to the role of
TNFR1 in EAN by using TNFR1 knockout mice [24,25]. The
discrepancy has been discussed in the latter publication [25].
Figure 3. Expression of IL-12 and IL-10 in stimulated macrophages. Thioglycollate elicited macrophages were harvested by standard lavage
of peritoneal exudates with 10 ml serum-free culture medium DMEM/F12, cultivated and stimulated with LPS plus IFN-c for 24 h. A. Macrophages
were assessed by flow cytometry. In both naı ¨ve and EAN mice, two subgroups of PEMs were presented. The right group of cells with larger size
(Subgroup 2) expressed higher levels of IL-6 and IL-12 (data not shown), compared with Subgroup 1, indicating a stronger activation of these cells. B.
and C. Cells in both groups expressed macrosialin (The red histograms denote the stainings of controls with FITC-conjugated isotype antibody and
the greens denote the stainings with anti-macrosialin antibody (Clone: ED1)). D. In EAN, the proportion of more activated PEMs was significantly
lower in TNF-a KO mice than in WT mice (p,0.05). E. Representative flow cytometric data show that after proinflammatory stimulation, macrophages
from TNF-a KO mice with EAN (blue histogram) expressed lower levels of IL-12 than from WT mice with EAN (green). The red histogram denotes the
staining with PE-conjugated isotype antibody. F. After proinflammatory stimulation, the proportion of IL-12
+ macrophages was significantly lower in
TNF-a KO mice than in WT mice (both naive and EAN). G. Representative flow cytometric data show that after proinflammatory stimulation,
macrophages from TNF-a KO mice with EAN (blue histogram) expressed higher levels of IL-12 than from WT mice with EAN (green). The red
histogram denotes the staining with PE-conjugated isotype antibody. H. After proinflammatory stimulation, the proportion of IL-10
+ macrophages
was significantly higher in TNF-a KO mice than in WT mice, independent of EAN induction. Data are presented as mean value 6 SD of one
representative out of three independent experiments (n=5 or 6 in each group). * p,0.05.
doi:10.1371/journal.pone.0038157.g003
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PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e38157Moreover, TNFR2 may compensate for the loss of TNFR1 roles
in TNFR1 KO mice, since TNFR1 and TNFR2 are known to
trigger overlapping intracellular signaling events (e.g. nuclear
factor kappa B) [26]. Regretfully, the functions of macrophages
were not investigated in those two studies. However, in
experimental autoimmune encephalomyelitis (EAE), an analogous
experimental disorder of EAN in the central nervous system,
TNFR1 KO mice were totally resistant to EAE, exhibiting
reduced antigen-specific proliferative responses and Th1 cytokine
production, whereas TNFR2 KO mice exhibited exacerbated
EAE, enhanced Th1 cytokine production, and enhanced macro-
phage and T cell infiltration [27]. To further elucidate which
receptor is responsible for the detrimental effect of TNF-a,w e
blocked the functions of TNFR1 in WT mice with EAN by using
anti-TNFR1 monoclonal antibodies. The clinical severity of EAN
was markedly mitigated after administration of this TNFR1
antagonist. However, this might also be due to the beneficial role
of TNF-a acting via TNFR2 [28,29]. Evidence showed that the
antiinflammatory effects of TNF-a are mediated via TNFR2 in
macrophages [30]. We then blocked the functions of TNFR1 in
both TNF-a KO and WT mice with EAN and corroborated the
detrimental role of TNFR1 in EAN.
Two main effector cells, T cells and macrophages, play critical
roles in the pathogenesis of EAN. However, TNF-a deficiency did
not change lymphocyte proliferation in response to antigenic or
mitogenic stimulant. Hence, we hypothesized that TNF-a de-
ficiency ameliorates the clinical severity of EAN via modulating
macrophage functions. Thus, we further focused our interest on
macrophages.
Activated macrophages can be divided into two distinct subsets:
classically activated macrophages (M1) and alternatively activated
macrophages (M2). Th1 cytokines such as IFN-c and IL-1b, and
Toll-like receptor agonists such as LPS and poly I:C induce the
M1 phenotype, which is characterized by enhanced production of
proinflammatory cytokines, e.g. IL-12, expression of MHC II
molecules, and generation of free radicals including NO [31]. M1
macrophages are considered to mediate host defence to infections,
but also to cause autoimmune tissue damage. M2 macrophages
are induced by Th2 cytokines and express high levels of
antiinflammatory molecules, e.g. IL-10, which underlines their
role in antiinflammation and tissue repair. A switch of macrophage
phenotype from M1 to M2 during EAN could favor the outcome
of EAN [32]. Compound A, a plant origin ligand of glucocorticoid
receptors attenuated EAN by increasing M2 macrophages [32].
We found a reduced ratio of IL-12/IL-10 in CE infiltrating cells
and a lower level of IL-12 in unstimulated PEMs from TNF-a KO
mice with EAN, indicating the proinflammatory M1 phenotype of
macrophages in EAN was down-regulated due to the TNF-
a deficiency.
To gain a deeper insight into the altered functions of
macrophages in TNF-a KO mice, we purified and cultivated
macrophages in vitro and manipulated the culture milieu by adding
various inflammatory stimuli. Before cultivation we found two
subgroups of macrophages with different light scatter properties,
i.e. larger, more activated versus smaller, less activated macro-
phages. The proportion of more activated macrophages (higher
levels of IL-6 and IL-12 expression) was lower in naı ¨ve than EAN
mice and lower in TNF-a KO than WT mice with EAN. After in
vitro stimulation with proinflammatory agents, macrophages from
TNF-a KO mice with EAN produced reduced levels of IL-12 and
IL-6 and increased levels of IL-10 compared with those from WT
mice with EAN. Moreover, a reduced production of NO was
detected in culture supernatants of macrophages from TNF-a KO
mice after proinflammatory stimulation. Previously, we reported
that 1400 W, a specific inducible nitric oxide synthase (iNOS)
inhibitor could remarkably suppress the clinical course of EAN
Figure 4. Production of IL-6, IL-10 and IL-12 in the culture supernatants of macrophages. A. Macrophages from naı ¨ve and EAN mice were
cultured with PBS or stimulated with LPS (100 ng/ml) plus IFN-c (100 IU/ml) for 24 h. Supernatants were collected for ELISA detection. Without
stimulation, macrophages from TNF-a KO mice (both naive and EAN mice) produced higher levels of IL-6 than those from WT mice, whereas after
stimulation, macrophages from TNF-a KO mice produced lower levels of IL-6 than those from WT mice. B. For IL-12, the cytokine level in cultures of
stimulated macrophages of TNF-a KO mice with EAN was significantly lower than WT mice with EAN. The level in cultures of stimulated macrophages
was also lower in the control group than in the EAN group (for both WT and TNF-a KO mice). C. For IL-10, an opposite result to IL-12 was registered,
i.e. stimulated and unstimulated macrophages from TNF-a KO mice with EAN produced higher levels of IL-10 than those from WT mice with EAN. As
for IL-12, naı ¨ve mice showed no significant differences. Data are presented as mean value 6 SD of one representative out of three independent
experiments (n=5 or 6 in each group). * p,0.01.
doi:10.1371/journal.pone.0038157.g004
Figure 5. NO production of cultured macrophages. PEMs from naı ¨ve and EAN mice were cultured and stimulated with LPS (100 ng/ml), IFN-c
(100 IU/ml), IL-12 (10 ng/ml), poly I:C (50 mg/ml), combinations thereof. In each set of stimulation, NO production was lower in the TNF-a KO group
than in the WT group (p,0.01 for all comparisons). Data are presented as mean value 6 SD of one representative out of three independent
experiments (n=5 or 6 in each group).
doi:10.1371/journal.pone.0038157.g005
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PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e38157[22]. The reduced production of NO in TNF-a KO mice may
explain the attenuated clinical severity of EAN. Taken together,
these findings indicate that TNF-a deficiency results in a shift to
the M2 phenotype or in a down-redulation of the M1 phenotype
after proinflammatory stimulation.
Th17 cells, which are characterized by production of IL-17,
have been shown to be independently capable of driving EAE
Figure 6. Tregs and IFN-c production. EAN mice were sacrificed at nadir of EAN (day 28 p.i.) and CE infiltrating cells were analyzed by flow
cytometry. A. Gating for Treg in CE infiltrating cells was shown. R1 represents CD4
+ T cells. R2 represents CD4
+CD25
+ cells, which were confirmed by
FoxP3 staining. B. In TNF-a KO mice, the number of FoxP3-expressing cells (blue histogram) is slightly increased compared to WT mice (green). The
red histogram denotes the staining with FITC-conjugated isotype antibody. C. The percentage of Tregs (CD4
+CD25
+FoxP3
+) relative to CD4
+ CE
infiltrating cells was higher in TNF-a KO than in WT mice with EAN. D. Representative flow cytometric data show that infiltrating cells from TNF-a KO
mice (blue histogram) expressed lower levels of IFN-c than from WT mice (green). The red histogram denotes the staining with FITC-conjugated
isotype antibody. E. The percentage of IFN-c
+ cells relative to CD4
+ CE infiltrating cells was significantly lower in TNF-a KO than in WT mice with EAN.
F. EAN mice were sacrificed at nadir of EAN (day 28 p.i.) and single cell suspensions of splenic MNCs were analyzed by flow cytometry. The
percentage of IFN-c expressing cells relative to CD4
+ splenic MNCs was lower in TNF-a KO than in WT mice with EAN. Data are presented as mean
value 6 SD of one representative out of three independent experiments (n=5 in each group). * p,0.05.
doi:10.1371/journal.pone.0038157.g006
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PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e38157Figure 7. IL-17A production. A. EAN mice were sacrificed at nadir of EAN (day 28 p.i.) and CE infiltrating cells were analyzed by flow cytometry.
Generic features of the cells as assessed by light scatter properties (FSC and SSC) in flow cytometry, are shown. B. R1 represents CD4
+ cells (.95%). C.
Representative flow cytometric data show that CD4
+ CE infiltrating cells from TNF-a KO mice (blue histogram) expressed higher levels of IL-17A than
from WT mice (green histogram). The red histogram denotes the staining with APC-conjugated isotype antibody. D. The percentage of CD4
+IL-17A
+
cells was higher in TNF-a KO than in WT mice with EAN. E. Also at nadir of EAN, single cell suspensions of splenic MNCs were analyzed by flow
cytometry. The percentage of CD4
+IL-17A
+ cells in spleen was elevated in EAN compared to naı ¨ve mice. Furthermore, it was significantly higher in
TNF-a KO mice than in WT mice. F. Serum samples at nadir of EAN (day 28 p.i.) were obtained and assessed. The concentrations of IL-17A were higher
in EAN TNF-a KO mice than in naı ¨ve TNF-a KO mice and higher in TNF-a KO mice than in WT mice with EAN. Data are presented as mean value 6 SD
of one representative out of three independent experiments (n=6 in each group). * p,0.05.
doi:10.1371/journal.pone.0038157.g007
TNF-a and EAN
PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e38157[33]. Interestingly, we found an upregulated production of IL-17A
in EAN versus naı ¨ve mice irrespective of the TNF-a gene status and
in TNF-a KO mice verus WT mice (both naı ¨ve and EAN). Since
Th1 cytokines antagonize the functions of Th17 cells [34], the
mitigated Th1 responses due to TNF-a deficiency might lead to
the enhanced Th17 response in TNF-a KO mice. Moreover, the
increased levels of IL-17A under EAN conditions compared to
naı ¨ve conditions, are strongly suggestive of a role of IL-17A in the
pathogenesis of EAN. In our another study, we found that IFN-c
deficiency exacerbated EAN via upregulating Th17 cells despite
a mitigated Th1 immune response [35]. The elevated levels of IL-
17A production may partially explain the incompletely inhibited
clinical course of EAN by TNF-a deficiency. Similar findings have
been reported in the treatment of the animal model of rheumatoid
arthritis with TNF-a and TNFR1 neutralizing antibodies [36].
Further studies are warranted to explore the clinical implications
of the increased levels of IL-17A in EAN under TNF-a deficient
conditions.
In summary, TNF-a deficiency and TNFR1 blockade re-
markably attenuated the clinical severity of EAN. Our findings
indicate that TNF-a exacerbates EAN by inducing the M1
phenotype of macrophages. The proinflammatory role of TNF-a in
EAN is probably mediated mainly by TNFR1.
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